

CURRICULUM VITAE

NAME: **Jian-Hua Mao, Ph.D.**
Position: Career Geneticist Staff Scientist
Address: Lawrence Berkeley National Laboratory
Biological Systems and Engineering Division
One Cyclotron Road, 977-225A
Berkeley, CA 94720
Phone: (510) 486-6204
Fax: (510) 495-2535
E-mail: JHMao@lbl.gov

EDUCATION:

B.Sc in Applied Mathematics, Southeast University, Nanjing, China, July 1986
M. Medical Sc in Biostatistics and Cancer Epidemiology,
Beijing Medical University (now Peking University Health Science Center),
Beijing, July 1989
Ph.D in Radiation Oncology, University of Glasgow, Glasgow, UK, July 1997

PRINCIPAL POSITION HELD:

1989-1991 Department of Biomathematics and Biostatistics, Beijing Medical University, China
Assistant Professor
1991-1993 Department of Public Health, University of Edinburgh, UK
Consultant
1999-2001 Cancer Research Institute, University of California San Francisco
Associate Specialist
2001-2002 Cancer Research Institute, University of California San Francisco
Specialist
2002-2008 Cancer Research Institute, University of California San Francisco
Associate Researcher
2007-2008 Department of Epidemiology and Biostatistics, University of California San Francisco
Assistant Adjunct Professor
2008-2011 Life Sciences Division, Lawrence Berkeley National Laboratory
Geneticist Staff Scientist
2011-present Life Sciences Division, Lawrence Berkeley National Laboratory
Career Geneticist Staff Scientist

AWARDS:

1988 Outstanding postgraduate awards from Beijing Medical University
1989 The first Prize from Chinese Society of Biomathematics and Biostatistics
1990 Outstanding Lecturer awards from Beijing Medical University
1991 The Second Prize from National Department of Health
1993-1996 Postgraduate Scholarships from University of Glasgow
1993-1996 Oversea Research Student Awards from Committee of Vice-Chancellor and Principals of the Universities of the United Kingdom
1995 Glasgow University Travel fellowship
2001-2004 Special Fellowship from the Leukemia and Lymphoma Society of America
2007 UCSF REAC Award

OTHER EXPERIENCE AND PROFESSIONAL MEMBERSHIPS:

- 2012-present, Epigenetics Society
- 2009-present, Radiation Research Society
- 2006, Society of Chinese Bioscientists in America
- 1999-present, American Association for Cancer Research
- 1993-present, British Association for Cancer Research
- 2013- Editorial Board, Dataset Papers in Science
- 2013- Editorial Board, New Journal of Science
- 2014- Editorial Board, Molecular Cytogenetics
- 2014- Academic Editor, PLoS ONE
- 2015- Editorial Board, Scientific Reports

PATENTS:

1. Jian-Hua Mao and Allan Balmain. Loss of FBXW7 is a Biomarker of Sensitivity to Treatment of Tumors with Inhibitors of mTOR. Patent#: WO2010030865.
2. Zhi Hu, Jian-hua Mao, Wen-Lin Kuo, Ge Huang, and Joe W. Gray. Cancer Specific Mitotic Network. Patent#: USA20120222139.
3. Weiguo Zhang, Jian-Hua Mao, Gary H Karpen. Use of centromere / kinetochore protein genes for cancer prognosis, diagnosis and treatment. Patent#: USA2015031413.

PENDING PATENTS:

1. Mao JH, Perez-Losada J, and Balmain A. Derivation of a mouse model for the generation of multiple epithelial tumor types. UCSF Disclosure#: SF2004-100 (2004).
2. Li Z, Mao JH, Balmain A, and Cai WW. A novel gene with tumor suppressing activity. UCSF Disclosure#: SF2006-050 (2006).
3. Yongwon Kwon and Jian-Hua Mao. A novel vectors, pFN-HA and pFC-HA for Tandem Affinity purification (TAP). LBNL Disclosure#: IB-3100 (2011).
4. Yongwon Kwon and Jian-Hua Mao. UBE2T, DTL, and NUF2 are a novel biomarker for cancer diagnosis, prognosis and therapy. LBNL Disclosure#: IB-3091 (2011).
5. Zeran Wang, Yueyong Liu, and Jian-Hua Mao. FAM83D is a novel biomarker for human cancer prognosis and potential therapeutical target. LBNL Disclosure#: 2013-027 (2012).
6. H.-Ulrich Weier, Jian-Hua Mao, A. A. Polyzos. Aurora Kinase A (AURKA) as antimitotic chemotherapy target in thyroid cancer. LBNL Disclosure#: 2013-131.

PUBLICATIONS:

Peer-reviewed Research – English:

1. Cameron DA, Leonard RCF, **Mao JH**, Prescott RJ. Identification of prognostic groups in follicular lymphoma. **Leukemia and Lymphoma**, 10: 89-99 (1993).
2. Leonard RCF, Prescott RJ, **Mao JH**, White JM. Successful application of a previously derived prognostic index in the analysis of randomised trial of 287 patients with high grade Non-Hodgkin's lymphoma. **Annals of Oncology**, 4: 853-856 (1993).
3. Ross WB, Leaver HA, Yap PL, Raab GM, Su BH, Carter DC, **Mao JH**, Qian W, Prescott RJ. Macrophage prostaglandin-E(2) and oxidative responses to endotoxin during immunosuppression associated with anesthesia and transfusion. **Prostaglandins Leukotrienes and Essential Fatty Acids**, 49: 945-953 (1993).
4. Steel JM, Johnstone FD, Hume R, **Mao JH**. Insulin requirements during pregnancy in women with type I diabetes. **Obstetrics and Gynecology**, 83: 253-258 (1994).
5. McMillan A, Pakianathan M, **Mao JH**, MaCintyre CCA. Urethral stricture and urethritis in men in scotland. **Genitourinary Medicine**, 70: 403- 405 (1994).

6. Campbell IA, Colman SB, **Mao JH**, Prescott RJ, Weston CFM. An open, prospective comparison of 2 agonists given via nebuliser, nebulhaler, or pressurised inhaler by ambulance crew as emergency. **Thorax**, 50: 79- 80 (1995).
7. **Mao JH**, Wheldon TE. A stochastic model for multistage tumorigenesis in developing and adult mice. **Mathematical Biosciences**, 129: 95-110 (1995).
8. Johnstone FD, Prescott RJ, Steel JS, **Mao JH**, Chambers S, Muir N. Clinical and ultrasound prediction of macrosomia in diabetic pregnancy. **British J of Obstetrics and Gynaecology**, 103: 747-754 (1996).
9. Ellard GA, Johnstone FD, Prescott RJ, Wang JX, **Mao JH**. Smoking during pregnancy: the dose dependence of birthweight deficits. **British J of Obstetrics and Gynaecology**, 103: 806-813 (1996).
10. Wheldon EG, Lindsay KA, Wheldon TE, **Mao JH**. A two-stage model for childhood acute lymphoblastic leukaemia: application to hereditary and non-hereditary leukaemogenesis. **Mathematical Biosciences**, 139: 1-24 (1997).
11. **Mao JH**, Lindsay KA, Balmain A, Wheldon TE. Stochastic modeling of tumorigenesis in p53 deficient mice. **British J of Cancer**, 77: 243-252 (1998).
12. Nibbs RJ, Yang J, Landau NR, **Mao JH**, Graham GJ. LD78 β , A non-allelic variant of human MIP-1 α (LD78 β), has enhanced receptor interactions and potent HIV suppressive activity. **J of Biological Chemistry**, 274: 17478 - 17483 (1999).
13. Nagase H, **Mao JH**, Balmain A. A subset of skin tumor modifier loci determines survival time of tumor-bearing mice. **Proc Natl Acad Sci USA**, 96: 15032-7 (1999).
14. Paxton JR, Bolger BS, Armour A, Symonds RP, **Mao JH**, Burnett RA. Apoptosis in cervical squamous carcinoma: predictive value for survival following radiotherapy. **J Clin Pathol**, 53:197-200 (2000).
15. Symonds P, Bolger B, Hole D, **Mao JH**, Cooke T. Advanced-stage cervix cancer: rapid tumour growth rather than late diagnosis. **British J Cancer**, 83: 566-568 (2000).
16. Johnstone FD, **Mao JH**, Steel JM, Prescott RJ, Hume R. Factors affecting fetal weight distribution in women with type I diabetes. **British J of Obstetrics and Gynaecology**, 107:1001-6 (2000).
17. Nagase H, **Mao JH**, de Koning JP, Minami T, Balmain A. Epistatic Interactions between Skin Tumor Modifier Loci in Interspecific (*spretus/musculus*) Backcross Mice. **Cancer Res**, 61:1305-1308(2001).
18. **Mao JH**, Lindsay KA, Mairs RJ, Wheldon TE. The Effect of Tissue-specific Growth Patterns of Target Stem Cells on the Spectrum of Tumours Resulting from Multistage Tumorigenesis. **J Theor Biol**, 210: 93-100 (2001).
19. Cai WW, **Mao JH**, Chow CW, Damani S, Balmain A, Bradley A. Genome-wide Detection of Chromosomal Imbalances in Tumors Using BAC Microarrays. **Nature Biotechnology**, 20: 393-396 (2002).
20. Ewart-Toland A, Briassouli P, de Koning JP, **Mao JH**, Yuan JW, Chan F, MacCarthy-Morrogh L, Ponder B, Nagase H, Burns J, West S, Linardopoulos S, Balmain A. Identification of *Aurora2/Stk6/STK15* as a candidate low penetrance tumor susceptibility gene in mouse and man. **Nature Genetics**, 43:403-412(2003).
21. Nagase H, **Mao JH**, Blamain A. Allele-specific *Hras* mutations and genetic alterations at tumor susceptibility loci in skin carcinomas from interspecific hybrid mice. **Cancer Res.**, 63:4849-4853 (2003).
22. **Mao JH**, Wu D, Perez-Losada J, Nagase H, DelRosario R, Balmain A. Genetic interactions between *Pten* and p53 in radiation-induced lymphoma development. **Oncogene**, 22:8379-85(2003).
23. **Mao JH**, To MD, Perez-Losada J, Wu D, Del Rosario R, Balmain A. Mutually exclusive mutations of the *Pten* and *ras* pathways in skin tumor progression. **Genes & Development**, 18: 1800-5(2004).
24. Fraga MF, Herranz M, Espada J, Ballestar E, Paz MF, Ropero S, Erkek E, Bozdogan O, Peinado H, Niveleau A, **Mao JH**, Balmain A, Cano A, Esteller M. A mouse skin multistage carcinogenesis model reflects the aberrant DNA methylation patterns of human tumors. **Cancer Res.**, 64:5527-34 (2004).
25. Li J, Jiang T, **Mao JH**, Balmain A, Peterson L, Harris C, Rao PH, Havlak P, Gibbs R, Cai WW. Genomic segmental polymorphisms in inbred mouse strains. **Nature Genetics**, 36:952-4 (2004).

26. **Mao JH**, Perez-Losada J, Wu D, Delrosario R, Tsunematsu R, Nakayama KI, Brown K, Bryson S, Balmain A. Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene. **Nature**, 432: 775-9 (2004).
27. Snijders AM, Nowak NJ, Huey B, Fridlyand J, Law S, Conroy J, Tokuyasu T, Demir K, Chiu R, **Mao JH**, Jain AN, Jones SJ, Balmain A, Pinkel D, Albertson DG. Mapping segmental and sequence variations among laboratory mice using BAC array CGH. **Genome Research**, 15: 302-11 (2005).
28. Ching TT, Maunakea AK, Jun P, Hong C, Zardo G, Pinkel D, Albertson DG, Fridlyand J, **Mao JH**, Shchors K, Weiss WA, Costello JF. Epigenome analyses using BAC microarrays identifies evolutionary conservation of tissue-specific methylation of SHANK3. **Nature Genetics**, 37: 645-651 (2005).
29. Perez-losada J, Wu D, DelRosario R, Balmain A, **Mao JH**. p63 and p73 do not contribute to p53 tumor suppressor activity in vivo. **Oncogene**, 24:5521-5524 (2005).
30. **Mao JH**, Li J, Jiang T, Li Q, Wu D, Perez-Losada J, DelRosario R, Peterson L, Balmain A, Cai WW. Genomic instability in radiation-induced mouse lymphoma from p53 heterozygous mice. **Oncogene**, 24: 7924-34 (2005).
31. **Mao JH**, Saunier EF, de Koning JP, McKinnon MM, Higgins MN, Nicklas K, Yang HT, Balmain A, Akhurst RJ. Genetic variants of *Tgfb1* act as context-dependent modifiers of mouse skin tumor susceptibility. **Proc Natl Acad Sci USA**, 103: 8125-8130 (2006).
32. To MD, Perez-Losada J, **Mao JH**, Hsu J, Jacks T, Balmain A. A Functional Switch From Lung Cancer Resistance to Susceptibility at the *Pas1* Locus in *Kras2^{LA2}* Mice. **Nature Genetics**, 38: 926-30 (2006).
33. **Mao JH**, Wu D, Perez-Losada J, Jiang T, Li Q, Neve RM, Gray JW, Cai WW, Balmain A. Crosstalk between Aurora-A and p53: frequent deletion or downregulation of Aurora-A in tumors from p53 null mice. **Cancer Cell**, 11:161-73 (2007).
34. Wakabayashi Y, **Mao JH**, Brown K, Girardi M, Balmain A. Promotion of Hras-induced squamous carcinomas by a polymorphic variant of the *Patched* gene in FVB mice. **Nature**, 445: 761-765 (2007).
35. de Koning JP, Wakabayashi Y, Nagase H, **Mao JH**, Balmain A. Convergence of congenic mapping and allele-specific alterations in tumors for the resolution of the *Skts1* skin tumor susceptibility locus. **Oncogene**, 26: 4171-4178 (2007).
36. Wei G, Ku S, Saito S, Tang AA, **Mao JH**, Appella E, Balmain A, Huang EJ. HIPK2 represses β -catenin-mediated Cyclin D1 Transcription: Role in Epidermal Stem Cells and Tumorigenesis. **Proc Natl Acad Sci USA**, 104:13040-5 (2007).
37. Guan Y, Kuo WL, Stilwell JL, Takano H, Lapuk AV, Fridlyand J, **Mao JH**, Yu M, Miller ME, Santos JL, Kalloger SE, Carlson JW, Ginzinger DG, Celniker SE, Huntman DG, Gray JW. Amplification of *PVT1* contributes to the pathophysiology of ovarian and breast cancer. **Clinical Cancer Res.**, 13: 5745-5755 (2007).
38. Chiaverotti T, Couto S, Donjacour A, **Mao JH**, Nagase H, Cardiff RD, Cunha GR, Balmain A. Dissociation of epithelial and neuroendocrine carcinoma lineages in the tramp model of prostate cancer. **American J of Pathology**, 172:236–246 (2008).
39. **Mao JH**, Kim IJ, Wu D, Climent J, Kang HC, DelRosario R, Balmain A. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. **Science**, 321: 1499-1502 (2008).
40. **Mao JH***, D Wu, R DelRosario, A Castellanos, A Balmain, J Perez-Losada. Monoallelic *Atm* Deficiency does not Increase Tumor Susceptibility to Ionizing Radiation Alone or in a *P53* Heterozygous Background. **Oncogene**, 27:6596-6600 (2008). *corresponding author
41. Mahler KL, Fleming J, Dworkin AM, Gladman N, Cho HY, **Mao JH**, Balmain A, Ewart Toland A. Sequence divergence of *Mus Spretus* and *Mus Musculus* across a skin cancer susceptibility locus. **BMC Genomics**, 9: 626 (2008).
42. Quigley DA, To MD, Pérez-Losada J, Pelorosso FG, **Mao JH**, Nagase H, Ginzinger DG, Balmain A. Genetic architecture of murine skin inflammation and tumor susceptibility. **Nature**, 485: 505-508 (2009).
43. Hung MS, Xu Z, Lin YC, **Mao JH**, Yang CT, Chang PJ, Jablons DM, You L. Identification of hematoin as a novel inhibitor of protein kinase CK2 from a natural product library. **BMC Cancer**, 9:135 (2009).

44. Li Z, Zhang Q, **Mao JH**, Weise A, Mrasek K, Fan X, Zhang X, Liehr T, Lu KH, Balmain A, Cai WW. An HDAC1-binding domain within FATS bridges p21 turnover to radiation-induced tumorigenesis. **Oncogene**, 29:2659-71 (2010).
45. Rocher-Ros V, Marco S, **Mao JH**, Gines S, Metzger D, Chambon P, Balmain A, Saura CA. Presenilin Regulates EGFR Signaling and Cell Transformation Through the Ubiquitin Ligase Fbw7. **Oncogene**, 29:2950-61 (2010).
46. Hu Z, Huang G, Sadanandam A, Gu S, Lenburg ME, Pai M, Bayani N, Blakely EA, Gray JW, **Mao JH**. The expression level of *HJURP* has an independent prognostic impact and predicts the sensitivity to radiotherapy in breast cancer. **Breast Cancer Res**, 12:R18 (2010).
47. Hung MS, Lin YC, **Mao JH**, Xu Z, Yang CT, Jablons DM, You L. Functional polymorphism of the *CK2 α* intronless gene plays oncogenic roles in lung cancer. **PLoS ONE**, 5:e11418 (2010).
48. Climent J, Perez-Losada J, Quigley DA, Kim IJ, Delrosario R, Jen KY, Bosch A, Lluch A, **Mao JH**, Balmain A. Deletion of the *hPER3* gene on chromosome 1p36 in recurrent ER-positive breast cancer. **Journal of Clinical Oncology**, 28: 3770-3778 (2010).
49. Chun MG, **Mao JH**, Chiu CW, Balmain A, Hanahan D. Polymorphic genetic control of tumor invasion in a mouse model of pancreatic neuroendocrine carcinogenesis. **Proc Natl Acad Sci USA**, 107:17268-73 (2010). PMID: PMC2951397
50. Hung MS, **Mao JH**, Xu Z, Yang CT, Yu JS, Harvard C, Lin YC, Bravo DT, Jablons DM, You L. *Cul4A* is an Oncogene in Malignant Pleural Mesothelioma. **J Cell Mol Med**, 15: 350-358 (2011).
51. Li T, Hung MS, Wang YC, **Mao JH**, Tan JL, Jahan K, Roos H, Xu Z, Jablons DM, You L. Transgenic Mice for Cre-Inducible Overexpression of the *Cul4A* Gene. **Genesis**, 49:134-41 (2011).
52. Nguyen DH, Oketch-Rabah HA, Illa-Bochaca I, Geyer FC, Reis-Filho JS, **Mao JH**, Ravani SA, Zavadil J, Borowsky AD, Jerry DJ, Dunphy KA, Seo JH, Haslam S, Medina D, Barcellos-Hoff MH. Radiation acts on the microenvironment to affect Breast carcinogenesis by distinct mechanisms that decrease breast cancer latency and affect tumor type. **Cancer Cell**, 19: 640-651 (2011).
53. Wang YV, Leblanc M, Fox N, **Mao JH**, Tinkum KL, Krummel K, Engle D, Piwnica-Worms D, Piwnica-Worms H, Balmain A, Kaushansky K, Wahl GM. Fine-tuning p53 activity through C-terminal modification significantly contributes to HSC homeostasis and mouse radiosensitivity. **Genes & Development**, 25: 1426-1438 (2011).
54. To MD, Quigley DA, **Mao JH**, DelRosario R, Hsu J, Hodgson G, Jacks T, Balmain A. Progressive genomic instability in the FVB/*Kras*^{LA2} mouse model of lung cancer. **Molecular Cancer Res.**, 9:1339-45 (2011).
55. Jen KY, Song IY, Banta KL, Wu D, **Mao JH**, Balmain A. Sequential mutations in Notch1, Fbxw7, and Tp53 in radiation-induced mouse thymic lymphomas. **Blood**, 119: 805-9 (2012).
56. Perez-Losada J, Wu D, DelRosario R, Balmain A, **Mao JH**. Allele-specific deletions in mouse tumors identify Fbxw7 as germline modifier of tumor susceptibility. **PLoS ONE**, 7: e31301 (2012).
57. **Mao JH**, Wu D, Kim IJ, Kang HC, Wei G, Climent J, Kumar A, Pelorosso FG, DelRosario R, Huang EJ, Balmain A. *Hipk2* cooperates with *p53* to suppress γ -ray radiation-induced mouse thymic lymphoma. **Oncogene**, 31: 1176–1180 (2012).
58. Ren S[#], Peng Z[#], **Mao JH**[#], Yu Y, Yin C, Gao X, Cui Z, Zhang J, Yi K, Xu W, Chen C, Wang F, Guo X, Lu J, Yang J, Wei M, Tian Z, Guan Y, Tang L, Xu C, Wang L, Gao X, Tian W, Wang J, Yang H, Wang J, Sun Y. RNA-seq analysis of prostate cancer in the Chinese population identifies recurrent gene-fusions, cancer associated long noncoding RNAs. **Cell Res.**, 22:806-21 (2012). [#]co-first author
59. Choi H, Kratz J, Pham P, Lee S, Ray R, Kwon YW, **Mao JH**, Kang HC, Jablons D, Kim IJ. Development of a rapid and practical mutation screening assay for human lung adenocarcinoma. **Int J Oncol.**, 40:1900-6 (2012).
60. Kwon Y, Kim IJ, Wu D, Lu J, Stock Jr WA, Liu Y, Huang Y, Kang HC, DelRosario R, Jen KY, Perez-Losada J, Wei G, Balmain A, **Mao JH**. Pten regulates Aurora-A and cooperates with Fbxw7 in modulating radiation-induced tumor development. **Molecular Cancer Res.**, 10: 834-844 (2012).

61. Zhang S, Wang Y, **Mao JH**, Hsieh D, Kim IJ, Hu LM, Xu Z, Long H, Jablons DM, You L. Inhibition of CK2 α Down-Regulates Hedgehog/Gli Signaling Leading to a Reduction of a Stem-Like Side Population in Human Lung Cancer Cells. **PLoS ONE**, 7: e38996 (2012).
62. Mulvihill MS, YW Kwon, S Lee, LT Fang, H Choi, R Ray, HC Kang, **JH Mao**, D Jablons, IJ Kim. Gremlin 1 is overexpressed in lung adenocarcinoma and increases cell growth and proliferation in normal lung cells. **PLoS ONE**, 7: e42264 (2012).
63. Wei G, Wang Y, Zhang P, Lu J, **Mao JH**. Evaluating the prognostic significance of FBXW7 expression level in human breast cancer by a meta-analysis of transcriptional profiles. **J Cancer Sci Ther**, 4: 299-305 (2012).
64. Li T, Hou SC, **Mao JH**, Wang YC, Lu XD, Tan JL, You B, Liu YP, Ni J, Au A, Jablons DM, Xu Z, You L. The Expression of Dishevelled-3 and Glutamine Metabolism in Malignant Pleural Mesothelioma. **Journal of Clinical Pathology**, 65: 855-8 (2012).
65. Ren S, Xu C, Cui Z, Yu Y, Xu W, Wang F, Lu J, Wei M, Lu X, Gao X, Liang Y, **Mao JH***, Sun Y*. Oncogenic CUL4A determines the response to thalidomide treatment in prostate cancer. **J Mol Med (Berl)**, 90: 1121-1132 (2012). * Co-Corresponding author
66. Snijders AM, Marchetti F, Bhatnagar S, Duru N, Han J, Hu Z, **Mao JH**, Gray JW, Wyrobek AJ. Genetic differences in transcript responses to low-dose ionizing radiation identify tissue functions associated with breast cancer susceptibility. **PLoS ONE**, 7: e45394 (2012).
67. Okumura K, Sato M, Saito M, Miura I, Wakana S, **Mao JH**, Miyasaka Y, Kominami R, Wakabayashi Y. Independent genetic control of early and late stages of chemically induced skin tumors in a cross of a Japanese wild derived inbred mouse strain, MSM/Ms. **Carcinogenesis**, 33:2260-8 (2012).
68. Liu Y, Ren S, Castellanos-Martin A, Perez-Losada J, Kwon YW, Huang Y, Wang Z, Abad M, Cruz-Hernandez JJ, Rodriguez CA, Sun Y, **Mao JH**. Multiple novel alternative splicing forms of FBXW7 α have a translational modulatory function and show specific alteration in human cancer. **PLoS ONE**, 7: e49453 (2012).
69. Lee DY, Bowen BP, Nguyen DH, Parsa S, Huang Y, **Mao JH**, Northen TR. Low-Dose Ionizing Radiation-Induced Blood Plasma Metabolic Response in a Diverse Genetic Mouse Population. **Radiat Res.**, 178: 551-555 (2012).
70. Liu Y, Huang Y, Wang Z, Huang Y, Li X, Louie A, Wei G, **Mao JH**. Temporal mTOR inhibition protects Fbxw7-deficient mice from radiation-induced tumor development. **Aging (Albany NY)**, 5: 111-119 (2013).
71. Nguyen DH, Fredlund E, Zhao W, Perou CM, Balmain A, **Mao JH**, Barcellos-Hoff MH. Murine microenvironment metaprofiles associate with human cancer etiology and intrinsic subtypes. **Clin Cancer Res**, 19: 1353-62 (2013).
72. Tang H, Xiao G, Behrens C, Schiller J, Allen J, Chow CW, Suraokar M, Corvalan A, **Mao JH**, White M, Wistuba II, Minna JD, Xie Y. A 12-Gene Set Predicts Survival Benefits from Adjuvant Chemotherapy in Non-Small-Cell Lung Cancer Patients. **Clin Cancer Res.**, 19: 1577-86 (2013).
73. Weier HU, **Mao JH**. Meta-analysis of Aurora kinase A (AURKA) expression data reveals a significant correlation between increased AURKA expression and distant metastases in human ER-positive breast cancers. **Journal of Data Mining in Genomics & Proteomics**, 4: 127(2013).
74. Louie KB, Bowen BP, McAlhany S, Huang Y, Price JC, **Mao JH**, Hellerstein M, Northen TR. Mass spectrometry imaging for in situ kinetic histochemistry. **Scientific Reports**, 3:1656 (2013).
75. Kim IJ, Quigley D, To MD, Pham P, Lin K, Jo B, Jen KY, Raz D, Kim J, **Mao JH**, Jablons D, Balmain A. Rewiring of human lung cell lineage and mitotic networks in lung adenocarcinomas. **Nat Commun**, 4:1701 (2013).
76. Kang HC, Wakabayashi Y, Jen KY, **Mao JH**, Zoumpourlis V, Del Rosario R, Balmain A. Ptch1 Overexpression Drives Skin Carcinogenesis and Developmental Defects in K14Ptch(FVB) Mice. **J Invest Dermatol**, 133:1311-20 (2013).
77. Wang Y, Liu Y, Lu J, Zhang P, Wang Y, Xu Y, Wang Z, **Mao JH***, Wei G*. Rapamycin inhibits FBXW7 loss-induced epithelial-mesenchymal transition and cancer stem cell-like characteristics in

- colorectal cancer cells. **Biochem Biophys Res Commun**, 434: 352-356 (2013). *Co-Corresponding author
78. Cui Z, Ren S, Lu J, Wang F, Xu W, Sun Y, Wei M, Chen J, Gao X, Xu C, **Mao JH**, Sun Y. The prostate cancer-up-regulated long noncoding RNA PlncRNA-1 modulates apoptosis and proliferation through reciprocal regulation of androgen receptor. **Urol Oncol**, 31:1117-23 (2013).
 79. Lu J, Wen M, Huang Y, He X, Wang Y, Wu Q, Li Z, Castellanos-Martin A, Abad M, Cruz-Hernandez JJ, Rodriguez CA, Pérez-Losada J, **Mao JH***, Wei G*. *C2ORF40* suppresses breast cancer cell proliferation and invasion through modulating expression of M phase cell cycle genes. **Epigenetics**, 8: 571-83 (2013). *Co-Corresponding author
 80. Hung MS, Xu Z, Chen Y, Smith E, **Mao JH**, Hsieh D, Lin YC, Yang CT, Jablons DM, You L. Hematein, a casein kinase II inhibitor, inhibits lung cancer tumor growth in a murine xenograft model. **Int J Oncol**, 43:1517-22 (2013).
 81. Wang Z, Liu Y, Zhang P, Zhang W, Wang W, Curr K, Wei G, **Mao JH**. FAM83D promotes cell proliferation and motility by downregulating tumor suppressor gene FBXW7. **Oncotarget**, 4: 2476-2486 (2013).
 82. Wang Y, Wen M, Kwon Y, Xu Y, Liu Y, Zhang P, He X, Wang Q, Huang Y, Jen KY, LaBarge MA, You L, Kogan SC, Gray JW, **Mao JH***, Wei G*. CUL4A induces epithelial-mesenchymal transition and promotes cancer metastasis by regulating ZEB1 expression. **Cancer Res.**, 74: 520-531(2014). *Co-Corresponding author
 83. Tang J, Fernandez-Garcia I, Vijayakumar S, Martinez-Ruiz H, Illa-Bochaca I, Nguyen DH, **Mao JH**, Costes SV, Barcellos-Hoff MH. Irradiation of juvenile, but not adult, mammary gland increases stem cell self-renewal and estrogen receptor negative tumors. **Stem Cells**, 32: 649-61 (2014).
 84. Yang YL, Hung MS, Wang Y, Ni J, **Mao JH**, Hsieh D, Au A, Kumar A, Quigley D, Fang LT, Yeh CC, Xu Z, Jablons DM, You L. Lung Tumorigenesis in a Conditional Cul4A Transgenic Mouse Model. **J Pathol**. 233:113-23 (2014).
 85. Snijders AM, Langley S, **Mao JH**, Bhatnagar S, Bjornstad KA, Rosen CJ, Lo A, Huang Y, Blakely EA, Karpen GH, Bissell MJ, Wyrobek AJ. An interferon signature identified by RNA-sequencing of mammary tissues varies across the estrous cycle and is predictive of metastasis-free survival. **Oncotarget**, 5: 4011-25 (2014).
 86. Hackett CS, Quigley DA, Wong RA, Chen J, Cheng C, Song YK, Wei JS, Pawlikowska L, Bao Y, Goldenberg DD, Nguyen K, Gustafson WC, Rallapalli SK, Cho YJ, Cook JM, Kozlov S, **Mao JH**, Van Dyke T, Kwok PY, Khan J, Balmain A, Fan QW, Weiss WA. Expression Quantitative Trait Loci and Receptor Pharmacology Implicate Arg1 and the GABA-A Receptor as Therapeutic Targets in Neuroblastoma. **Cell Reports**, 9: 1034-1046.
 87. Wang Y, Zhang P, Liu Z, Wang Q, Wen M, Wang Y, Yuan H, **Mao JH**, Wei G. CUL4A overexpression enhances lung tumor growth and sensitizes lung cancer cells to Erlotinib via transcriptional regulation of EGFR. **Molecular Cancer**, 13:252 (2014).
 88. Illa-Bochaca I, Ouyang H, Tang J, Sebastiano C, **Mao JH**, Costes SV, Demaria S, Barcellos-Hoff MH. Densely ionizing radiation acts via the microenvironment to promote aggressive *Trp53* null mammary carcinomas. **Cancer Res**, 74:7137-48 (2014).
 89. Nguyen DH, Ouyang H, **Mao JH**, Hlatky L, Barcellos-Hoff MH. Distinct luminal type mammary carcinomas arise from orthotopic *Trp53* null mammary transplantation of juvenile versus adult mice. **Cancer Res**, 74: 7149-58 (2014).
 90. Tang J, Huang Y, Nguyen DH, Costes SV, Snijders AM, **Mao JH**. Genetic background modulates lncRNA-coordinated tissue response to low dose ionizing radiation. **Int J Genomics**, 2015: 461038 (2015).
 91. Castellanos-Martín A, Castillo-Lluva S, del Mar Sáez-Freire M, Blanco-Gómez A, Hontecillas-Prieto L, Patino-Alonso C, Galindo-Villardón P, Pérez del Villar L, Martín-Seisdedos C, Isidoro-García M, del Mar Abad-Hernández M, Cruz-Hernández JJ, Rodríguez-Sánchez CA, González-Sarmiento R, Alonso-López D, de las Rivas J, García-Cenador B, García-Criado J, Lee DY, Bowen B, Reindl W, Northen T*,

- Mao JH***, Pérez-Losada J*. Unraveling heterogeneous susceptibility and progression of erbb2-breast cancer by a systems biology approach. **Genome Biology**, 16:40 (2015). *Co-Corresponding author
92. Zhang P, Lo A, Huang Y, Huang G, Liang G, Mott J, Karpen GH, Blakely EA, Bissell MJ, Barcellos-Hoff MH, Snijders AM, **Mao JH**. Identification of genetic loci that control mammary tumor susceptibility through the host microenvironment. **Scientific Reports**, 5: 8919 (2015).
 93. You B, Yang YL, Xu Z, Dai Y, Liu S, **Mao JH**, Tetsu O, Li H, Jablons DM, You L. Inhibition of ERK1/2 down-regulates the Hippo/YAP signaling pathway in human NSCLC cells. **Oncotarget**, 6:4357-68 (2015).
 94. Hang M, Huang Y, Snijders AM, **Mao JH**. Genetic background influences loss of heterozygosity patterns in radiation-induced mouse thymic lymphoma. **Journal of Nature and Science**, 1: e96 (2015).
 95. Wang Y, Xu Z, **Mao JH**, Hsieh D, Au A, Jablons DM, Li H, You L. PR-Set7 is Degraded in a Conditional Cul4A Transgenic Mouse Model of Lung Cancer. **Zhongguo Fei Ai Za Zhi**. 18: 345-50 (2015).
 96. Wang Y, Xu Z, **Mao JH**, Hung MS, Hsieh D, Au A, Jablons DM, You L. Analysis of lung tumor initiation and progression in transgenic mice for Cre-inducible overexpression of Cul4A gene. **Thoracic Cancer**, 6: 480-487 (2015).
 97. Zhan P, Wang Y, Zhao S, Liu C, Wang Y, Wen M, **Mao JH**, Wei G, Zhang P. FBXW7 negatively regulates ENO1 expression and function in colorectal cancer. **Lab Invest**, 95: 995-1004 (2015).
 98. Castillo-Lluva S, Hontecillas-Prieto L, Blanco-Gómez A, Del Mar Sáez-Freire M, García-Cenador B, García-Criado J, Pérez-Andrés M, Orfao A, Cañamero M, **Mao JH**, Gridley T, Castellanos-Martín A, Pérez-Losada J. A new role of SNAI2 in postlactational involution of the mammary gland links it to luminal breast cancer development. **Oncogene**, 34:4777-90 (2015).
 99. Yang YL, Ni J, Hsu PC, **Mao JH**, Hsieh D, Xu A, Chan G, Au A, Xu Z, Jablons DM, You L. Cul4A overexpression associated with Gli1 expression in malignant pleural mesothelioma. **J Cell Mol Med**, 19: 2385-96 (2015).
 100. Wen M, Kwon Y, Wang Y, **Mao JH***, Wei G*. Elevated expression of UBE2T exhibits oncogenic properties in human prostate cancer. **Oncotarget**, 6: 25226-39 (2015). *Co-Corresponding author.
 101. Xu B, Chen M, Yao M, Ji X, Mao Z, Tang W, Qiao S, Schick SF, **Mao JH**, Hang B, Xia Y. Metabolomics reveals metabolic changes in male reproductive cells exposed to thirdhand smoke. **Scientific Reports**, 5:15512 (2015).
 102. Hung MS, Chen IC, You L, Jablons DM, Li YC, Mao JH, Xu Z, Hsieh MJ, Lin YC, Yang CT, Liu ST, Tsai YH. Knockdown of Cul4A increases chemosensitivity to gemcitabine through upregulation of TGFBI in lung cancer cells. **Oncol Rep**, 34: 3187-3195 (2015).
 103. **Mao JH***, Langley SA, Huang Y, Hang M, Bouchard K, Celniker SE, Brown JB, Jansson JK, Karpen GH, Snijders AM. Identification of genetic factors that modify motor performance and body weight using Collaborative Cross mice. **Scientific Reports** in Press. Corresponding author.
 104. Snijders AM, Liu Y, Su L, Huang Y, **Mao JH**. Expression profiling reveals transcriptional regulation by Fbxw7/mTOR pathway in radiation-induced mouse thymic lymphomas. **Oncotarget** in press
 105. Adams CJ, Yu JS, **Mao JH**, Jen KY, Costes SV, Wade M, Shoemake J, Aina OH, Del Rosario R, Menchavez PT, Cardiff RD, Wahl GM, Balmain A. The Trp53 delta proline (Trp53 Δ P) mouse exhibits increased genome instability and susceptibility to radiation-induced, but not spontaneous, tumor development. **Mol Carcinog**. 2015 Aug 27. doi: 10.1002/mc.22377. [Epub ahead of print]
 - 106.

Peer-reviewed Reviews– English:

1. **Mao JH***, Balmain A. Genomic approaches to identification of tumour-susceptibility genes using mouse models. **Curr Opin Genet Dev**, 13: 14-9 (2003). *corresponding author

2. de Koning JP, **Mao JH**, Balmain A. Novel approaches to identify low penetrance cancer susceptibility genes using mouse models. **Recent Results Cancer Res.**, 163:19-27(2003).
3. Perez-losada J, **Mao JH**, Balmain A. Control of genomic instability and epithelial tumor development by the p53-Fbxw7/Cdc4 pathway. **Cancer Res.**, 65: 6488-92 (2005).
4. To MD, Perez-Losada J, **Mao JH**, Balmain A. Crosstalk between Pten and Ras signaling pathways in tumor development. **Cell Cycle**, 4: 1185-1188 (2005).
5. Climent J, **Mao JH**, Garcia JL, Arsuaga J, Perez-Losada J. Characterization of breast cancer by array CGH. **Biochemistry and Cell Biology**, 85:497-508 (2007).
6. Pérez-Losada J, Castellanos-Martín A, **Mao JH**. Cancer Evolution and Individual Susceptibility. **Integrative Biology**, 3: 316-328 (2011). PMID: PMC3125395
7. Xu R, **Mao JH**. Gene transcriptional networks integrate microenvironmental signals in human breast cancer. **Integrative Biology**, 3: 368-374 (2011).
8. Barcellos-Hoff MH, Adams C, Balmain A, Costes SV, Demaria S, Illa-Bochaca I, **Mao JH**, Ouyang H, Sebastiano C, Tang J. Systems biology perspectives on the carcinogenic potential of radiation. **J Radiat Res**, 55 Suppl 1:i145-i154 (2014).
9. **Mao JH**, Weier HUG. Bioinformatics applications in biological and clinical studies. **J Data Mining Genomics Proteomics**, 5: e114 (2014).
10. **Mao JH**, Snijders AM. Low-dose radiation cancer susceptibility models. **Aging (Albany NY)**, 7: 352-353 (2015).

Chapters in books:

1. **Mao JH** and Wheldon TE. Multistage models for radiation tumorigenesis in p53 deficient transgenic mice: computer simulation of the effect of single doses of radiation. In: 'Advances in Mathematical Population Dynamics: Molecules, Cells and Man', edited by Arino O., Axelrod D. and Kimmel M., London: World Scientific. pp241-253.
2. Nagase H, Frame S, **Mao JH**, Balmain A. Genetic control of tumor predisposition and progression in mice. In "New Frontiers in Mechanistic Cancer Research in Animal Models" (eds Cohen S, Hino O, Ishikawa T, Nakagama H, Shirai T, Sugimura T), Princess Takamatsu Cancer Research Fund, Tokyo, 22-26 (1999).